p21(WAF1/CIP1) and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: A p53+, MDM2-, p21- immunophenotype associated with missense p53 mutations

Journal of Pathology

Volumn 181, Issue 1, 1997, Pages 51-61

  Villuendas, R ^a   Pezzella, F ^b   Gatter, K ^c   Algara, P ^a   Sanchez Beato M ^a   Martinez P ^a   Martinez J C ^a   Munoz K ^a   Garcia P ^a   Sanchez L ^a   Kocialkowsky, S ^c   Campo, E ^d   Orradre, J L ^a   Piris, M A ^a,e  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HOSPITAL CLÍNIC   (Spain)

^e Department of Pathology   (Spain)

Author keywords

MDM2 protein; non Hodgkin's lymphoma; p21(WAF1 CIP1) protein; p53 mutations

Indexed keywords

PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; TUMOR PROTEIN;

ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; ENZYME IMMUNOASSAY; GENE EXPRESSION; IMMUNOPHENOTYPING; ISOLATION AND PURIFICATION; METABOLISM; MUTATION; TONSIL; VIROLOGY;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION; GENES, P53; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; LYMPHOMA, NON-HODGKIN; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TONSIL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030615220     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199701)181:1<51::AID-PATH689>3.0.CO;2-N     Document Type: Article

References (51)

1. Yin Y, Tainsky MA, Farideh ZB, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1993; 70: 937.
2. Aloni-Grinstein R, Zan-Bar I, Alboum I, Goldfinger N, Rotter V. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene 1993; 8: 3297.
3. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1993; 352: 345.
4. Unger T, Nau MM, Segal S, Minna JD. p53, a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 1992; 11: 1383.
5. Kastan MB, Zhan Q, EJ-Dejry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 1992; 71: 587.
6. Barak Y, Juven T, Haffner R, Oren M. MDM2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461.
7. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993: 7: 1126.
8. Chen CY, Oliner JD, Zhan Q, Fornace AJ, Vogelstein B, Kastan MB. Interactions between p53 and MDM2 in mammalian cell cycle check point pathway. Proc Natl Acad Sci USA 1994; 91: 2684.
9. El-Diery WS, Tokino T, Velculescu VE, et al. WAF1. a potential mediator of p53 tumor suppression. Cell 1993; 75: 817.
10. Zhan Q, Fan S, Bae I, et al Induction of BAX by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994; 9: 3743.
11. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582.
12. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805.
13. Xiong P, Hannon G, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701.
14. Waga S, Hannon GJ, Beach D, Stillman B, The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574.
15. Flores-Rozas H, Kelman Z, Dean FB, et al. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci USA 1994; 91: 8655.
16. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013-1024.
17. Parker SB, Eichele G, Zhang P, et al. p53-independent expression of p21/Cip1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024.
18. Macleod KF, Sherry N, Hannon G, et al. p53-dependent and independent expression of p21 during cell growth, differentiation and DNA damage. Genes Dev 1995; 9: 935.
19. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857.
20. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80.
21. Reiferberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736.
22. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995; 55: 2910-2919.
23. DiGiuseppe JA, Redston M, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-888.
24. Villuendas R, Piris MA, Algara P, et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993; 82: 3151.
25. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 1993; 143: 845-856.
26. Piris MA, Pezzella F, Martinez-Montero JC, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 1994, 69: 337-341.
27. Louie DC, Offit K, Jaslow R, et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 1995; 86: 2892-2899.
28. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howly PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promoted the degradation of p53. Cell 1990; 63: 1129.
29. Ueda H, Ullrich SJ, Gangemi JD, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nature Genet 1995; 9: 41
30. Reid RL, Lindholm PF, Mireskandari A, Dittmer J. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-1. Oncogene 1993; 8: 3029.
31. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG. EBNA-5, an Epstein-Barr virus encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 1993; 90: 5455
32. Joske D. Knetch H. Epstein Barr virus in lymphomas: a review. Blood Rev 1993; 7: 215-222.
33. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361.
34. Norton AJ, Jordan S, Yeomans P. Brief high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994; 173: 371-379.
35. Cance WG, Brennan MF, Dudas ME, Huang CM, Cordon-Cardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990; 323: 1457-1462.
36. Esteban JM, Battifora H, Warsi Z, Bailey A, Bacus S. Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod Pathol 1991; 4: 53-57.
37. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. 1989.
38. Fey MF, Pilkington SP, Summers P, Wainscoat JS. Molecular diagnosis of haematological disorders using DNA from stored bone marrow slides. Br J Haematol 1987; 67: 489.
39. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874.
40. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988; 70: 245.
41. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413.
42. Kocialkowski S, Pezzela F, Morrison H, et al. Mutations in the p53 gene are not limited to classic 'hot spots' and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haematol 1995; 89: 55.
43. Knetch H, Sahli R, Shaw P, et al. Detection of EBV DNA by PCR in lymph node biopsies from patients with angioimmunoblastic lymphadenopathy. Br J Haematol 1990; 75: 610.
44. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1602.
45. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252: 1708.
46. Kern SE, Pietenpol JA, Thiagalingan S, Seymon A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 as a sequence-specific DNA-binding protein. Science 1992; 256: 827.
47. Barak Y, Juven T, Hafner R, Oren M. MDM2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461-468.
48. El-Deiry WS, Harper JW, O'Connor PM, et al. p21 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169.
49. Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158.
50. Maestro R, Gloghini A, Dogliono C, et al. MDM2 overexpression does not account for stabilization of wild type p53 protein in non-Hodgkin's lymphomas. Blood 1995; 11: 3329.
51. Price BD, Park S. DNA damage increases the levels of MDM2 messenger RNA in wt-p53 human cells. Cancer Res 1994; 54: 896.